The report published today by the Academy of Medical Sciences describes an urgent and serious challenge about how we ensure that patients, their carers and the healthcare professionals that support them, feel able to trust their medicines and the research evidence that underpins them.
Earlier this week the British Medical Journal (BMJ) published and publicised a story which we believe inaccurately depicts the work of the pharmaceutical industry in the UK. Our chief executive Mike Thompson has written a letter to the BMJ in response.
New data shows research and development spend up to £254 million and a revised consent to disclose figure of 55%.
Following a BBC news story [Wednesday 1 March] reporting that the Hepatitis C Trust took funding from the pharmaceutical industry, the ABPI has responded by highlighting guidance produced in partnership with National Voices, as well as the ABPI Code of Practice.
On January 17, Health Ministers from OECD countries will gather in Paris to discuss how healthcare systems can reform to better deal with the challenges and to realize the opportunities of tomorrow. Important milestones are on the agenda including how to tackle ineffective spending in healthcare and...
The publication of the Caldicott Review marks the next stage of how as a nation we will best manage and use our health and care data for the benefit of patients. The Review sets out detailed recommendations on data security and the terms for consent/opt-out which will be carefully reviewed and...
Read our CEO's guest blog post about the work of the Ethical Standards in Life Sciences Group on the BMJ website.
A very warm welcome to our November Conference. Welcome to our speakers and panellists from across academia, industry and the healthcare sector. And to Mike Farrar who will follow me shortly.
Now that my first few months have passed and I have had a chance to settle in, I would like to publically introduce myself as the new CEO of the ABPI to all of our members, our stakeholders and the wider public.
Deepak Khanna talks about his roles as both Managing Director at MSD and also as the new President of the ABPI in this pharmaphorum interview.